Metis Precision Medicine translates cancer research into precision therapies by utilizing genomic profiling to tailor treatments to individual patient needs. This approach addresses the challenge of ineffective one-size-fits-all cancer treatments, improving patient outcomes through personalized medicine.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional cancer treatments often follow a one-size-fits-all approach, which can be ineffective due to the unique genomic characteristics of each patient's cancer. This can lead to suboptimal outcomes and unnecessary side effects.
Solution
Metis Precision Medicine leverages genomic profiling to personalize cancer treatments, tailoring therapies to the specific genetic makeup of each patient's tumor. By analyzing the genomic data, Metis identifies the most effective treatment options, potentially improving patient outcomes and minimizing adverse effects. This approach aims to translate cancer research findings into clinically actionable insights, enabling oncologists to make more informed decisions about treatment strategies. Metis operates as a B-corp, emphasizing its commitment to social and environmental responsibility in its mission to advance precision medicine in cancer care.
Target Audience
The primary target audience includes oncologists and cancer patients seeking personalized treatment options based on genomic profiling.
Features
- Genomic profiling of patient tumor samples to identify unique genetic mutations and biomarkers.
- Personalized treatment recommendations based on the genomic profile of the cancer.
- Translation of cancer research findings into clinically relevant insights.